APP and Alzheimer disease: In another mouse model of AD (APP/PS1), senolytic treatment, using a combination of dasatinib and quercetin that reduced the burden of senescent cells associated with amyloid plaque, lowered Aβ load, reduced neuroinflammation, and reduced cognitive defects [58].